AI
BLUE

Axiom Investors’s bluebird bio BLUE Stock Holding History

Axiom Investors’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-1,134
Closed -$2.47M – 133
2015
Q2 		$2.47M Sell
1,134
-95
-8% -$194K 0.07% 96
2015
Q1 		$1.92M Buy
+1,229
New +$1.62M 0.05% 115

Other funds holding BLUE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Axiom Investors's BLUE Position: Q3 2015 in Review

Axiom Investors sold out of bluebird bio (BLUE) in Q3 2015, closing a stake of 1,134 shares — an estimated $2.47M sold.

Axiom Investors first reported a position in BLUE in Q1 2015 and held it in 2 quarters. The position peaked at $2.47M in Q2 2015. 192 funds tracked by Wall St. Rank hold BLUE as of Q3 2015.

  • Axiom Investors reported no remaining bluebird bio position as of Q3 2015 after selling out during the quarter.
  • Axiom Investors sold 1,134 bluebird bio shares in Q3 2015, an estimated $2.47M.
  • Axiom Investors first reported a position in bluebird bio in Q1 2015 and held it in 2 quarters.
  • Axiom Investors's bluebird bio position peaked at $2.47M in Q2 2015.
  • 192 funds tracked by Wall St. Rank held bluebird bio as of Q3 2015.

Based on Axiom Investors's 13F filing for Q3 2015, filed 13 Nov 2015.